Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine and metabolic disorder affecting up to 20% of women in India. Conventional therapies often fail to address its multifactorial etiology and have limitations due to side effects. Siddha medicine, an ancient South Indian system, offers multimodal interventions that target hormonal, metabolic, and inflammatory pathways. This review aimed to evaluate the pharmacological basis, clinical evidence, and integration prospects of Siddha formulations in PCOS management.We conducted a scoping review of Siddha formulations commonly used in PCOS, such as Ashokarishtam, Karisalai Karpam, Amukkara Choornam, and Keezhanelli, analyzing preclinical and clinical evidence, proposed mechanisms of action, and safety considerations. Data were extracted from published experimental and clinical studies, Siddha classics, and pharmacological reviews. Siddha medicine offers a promising, culturally sensitive adjunct in PCOS management, addressing its complex pathophysiology. Well-designed trials and standardization are needed to substantiate efficacy and ensure safety for wider clinical adoption.
Abarnadevika et al. (Wed,) studied this question.